HER2-TARGETED THERAPIES
Cardioncological Approach for Trastuzumab Therapy in Breast Cancer Patients With Cardiotoxicity: Impact on Adherence and Clinical Outcome
Investigators evaluating adherence to and continuation of trastuzumab therapy among patients with HER2-positive breast cancer found that a dedicated cardioncological approach, including close clinical and imaging assessment such as prompt heart failure (HF) treatment, enabled patients to resume and complete trastuzumab treatment, with better overall survival and fewer HF events, compared to patients in the standard approach arm.
Frontiers in Pharmacology
